Recently, a Phase I clinical study on advanced HCC showed that patients showed good tolerance and potential therapeutic effects of a vaccine mixture containing NEIL3 peptide, which presents a new perspective for the treatment of HCC and deserves to be explored in depth [76]. This evidence concerns the gene NEIL3 and hepatocellular carcinoma.